True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 3, 2015 | Series C | $40M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Cowen Investment Management | — | Series C |